We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

33 hedge funds and large institutions have $8.72M invested in Protalix BioTherapeutics in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

14% more funds holding

Funds holding: 29 → 33 (+4)

0.27% less ownership

Funds ownership: 2.23% → 1.96% (-0.27%)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

30% less capital invested

Capital invested by funds: $12.5M → $8.72M (-$3.75M)

Holders
33
Holders Change
+4
Holders Change %
+13.79%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$2.14M
2
IAM
Ion Asset Management
Israel
+$1.8M
3
UOC
UBS O'Connor
Illinois
+$1.79M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$958K
5
AGC
Angelo Gordon & Co
New York
+$472K

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$7.43M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$3.56M
3
Barclays
Barclays
United Kingdom
-$219K
4
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$29K
5
SIM
Spark Investment Management
New York
-$16.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$2.13M +$2.14M +477,980 New
IAM
2
Ion Asset Management
Israel
$1.8M +$1.8M +403,501 New
UOC
3
UBS O'Connor
Illinois
$1.78M +$1.79M +400,000 New
Federated Hermes
4
Federated Hermes
Pennsylvania
$954K +$958K +214,343 New
AGC
5
Angelo Gordon & Co
New York
$470K +$472K +105,707 New
California Public Employees Retirement System
6
California Public Employees Retirement System
California
$356K – – –
Citigroup
7
Citigroup
New York
$260K +$261K +58,479 New
Renaissance Technologies
8
Renaissance Technologies
New York
$213K +$133K +29,840 +165%
Jane Street
9
Jane Street
New York
$173K +$167K +37,397 +2,712%
Deutsche Bank
10
Deutsche Bank
Germany
$138K – – –
BCM
11
Bridgeway Capital Management
Texas
$135K – – –
Parallax Volatility Advisers
12
Parallax Volatility Advisers
California
$63K +$63.2K +14,152 New
Millennium Management
13
Millennium Management
New York
$49K +$49.2K +11,010 New
BG
14
BlackRock Group
United Kingdom
$48K – – –
GC
15
Guggenheim Capital
Illinois
$18K – – –
HIIFS
16
Harel Insurance Investments & Financial Services
Israel
$18K – – –
Goldman Sachs
17
Goldman Sachs
New York
$18K +$36 +8 +0.2%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$17K +$12.2K +2,726 +260%
Citadel Advisors
19
Citadel Advisors
Florida
$17K +$16.7K +3,732 New
Northern Trust
20
Northern Trust
Illinois
$14K +$268 +60 +2%
SIM
21
Spark Investment Management
New York
$10K -$16.7K -3,730 -61%
PVH
22
Psagot Value Holdings
Israel
$10K +$89 +20 +0.9%
Barclays
23
Barclays
United Kingdom
$9K -$219K -49,000 -96%
NCCM
24
Nine Chapters Capital Management
New Jersey
$9K +$9.52K +2,130 New
WS
25
Wedbush Securities
California
$8K -$5.36K -1,200 -40%
1
2

PLX Hedge Fund Activity: Q4 2016 in Review

33 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2016, worth a combined $8.72M — down 30% from $12.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new PLX positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $2.14M. The largest seller was Camber Capital Management, exiting entirely with an estimated $7.43M sold.

  • 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2016, up from 29 in Q3 2016.
  • Funds reported $8.72M of Protalix BioTherapeutics stock for Q4 2016, down 30% quarter-over-quarter.
  • 11 funds opened new Protalix BioTherapeutics positions in Q4 2016 and 7 closed out, a net change of +4 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2016 was Highbridge Capital Management, an estimated $2.14M added.
  • The largest Protalix BioTherapeutics seller in Q4 2016 was Camber Capital Management, an estimated $7.43M sold.

Based on aggregated 13F filings for Q4 2016.